Updated Jul 16, 2026
Onyia Jude has filed 4 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $14.22M.

Jude Onyia is the Chief Scientific Officer at Neurocrine Biosciences Inc, a company focused on developing treatments for neurological and endocrine disorders. He has been involved in multiple SEC filings related to his role, indicating active participation in the company's scientific endeavors.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-09 | NBIX | NEUROCRINE BIOSCIENCES INC | G — Bona-fide gift | 2.4K | $0.00 | |
| 2026-06-02 | NBIX | NEUROCRINE BIOSCIENCES INC | S — Open-market sale | 11.0K | $160.25 | $1.76M |
| 2026-06-02 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 11.0K | $84.74 | $932K |
| 2026-05-29 | NBIX | NEUROCRINE BIOSCIENCES INC | S — Open-market sale | 11.0K | $155.53 | $1.71M |
| 2026-05-29 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 11.0K | $84.74 | $932K |
| 2026-02-24 | NBIX | NEUROCRINE BIOSCIENCES INC | G — Bona-fide gift | 3.1K | $0.00 | |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | F — Tax withholding / forfeiture | 10.8K | $124.12 | $1.33M |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | A — Grant or award | 19.9K | $0.00 | |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | F — Tax withholding / forfeiture | 1.5K | $124.12 | $182K |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 2.7K | $0.00 | |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | F — Tax withholding / forfeiture | 1.5K | $124.12 | $180K |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 2.7K | $0.00 | |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | F — Tax withholding / forfeiture | 1.4K | $123.10 | $176K |
| 2026-02-17 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 2.6K | $0.00 | |
| 2026-02-03 | NBIX | NEUROCRINE BIOSCIENCES INC | F — Tax withholding / forfeiture | 142 | $136.06 | $19K |
| 2026-02-03 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 238 | $0.00 | |
| 2025-09-03 | NBIX | NEUROCRINE BIOSCIENCES INC | G — Bona-fide gift | 1.5K | $0.00 | |
| 2025-08-05 | NBIX | NEUROCRINE BIOSCIENCES INC | G — Bona-fide gift | 3.1K | $0.00 | |
| 2025-07-09 | NBIX | NEUROCRINE BIOSCIENCES INC | S — Open-market sale | 59.8K | $130.46 | $7.80M |
| 2025-07-09 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 59.8K | $84.74 | $5.07M |
Jude Onyia is the Chief Scientific Officer at Neurocrine Biosciences Inc, a company focused on developing treatments for neurological and endocrine disorders. He has been involved in multiple SEC filings related to his role, indicating active participation in the company's scientific endeavors.…
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($14.22M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Onyia Jude profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.